Spirochete antigens persist near cartilage after murine Lyme borreliosis therapy

Journal of Clinical Investigation

Volumn 122, Issue 7, 2012, Pages 2652-2660

  Bockenstedt, Linda K ^a   Gonzalez, David G ^a   Haberman, Ann M ^a   Belperron, Alexia A ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL ANTIGEN; BACTERIAL DNA; CEFTRIAXONE; DOXYCYCLINE; GREEN FLUORESCENT PROTEIN; IMMUNOGLOBULIN G ANTIBODY; SPIROCHETE ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ACHILLES TENDON; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANKLE; ANTIBIOTIC THERAPY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIUM CULTURE; BACTERIUM DETECTION; BORRELIA BURGDORFERI; CARTILAGE; CONTROLLED STUDY; CYTOKINE PRODUCTION; EAR; HEART; IMAGING; IMMUNE RESPONSE; IMMUNIZATION; IN VITRO STUDY; INTRAVITAL MICROSCOPY; LYME DISEASE; MACROPHAGE; MICROSCOPY; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PERSISTENT INFECTION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TIBIOTARSAL JOINT; TISSUE HOMOGENATE; XENODIAGNOSIS;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTIGENS, BACTERIAL; ARTHRITIS, INFECTIOUS; BACTERIAL LOAD; BORRELIA BURGDORFERI; CARTILAGE; CEFTRIAXONE; DOXYCYCLINE; EAR, EXTERNAL; FEMALE; FLUORESCENCE RECOVERY AFTER PHOTOBLEACHING; GREEN FLUORESCENT PROTEINS; JOINT CAPSULE; LYME DISEASE; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; MICE, KNOCKOUT; MICROSCOPY, FLUORESCENCE, MULTIPHOTON; MYELOID DIFFERENTIATION FACTOR 88; PATELLA; RECOMBINANT PROTEINS;

EID: 84863541924     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI58813     Document Type: Article

References (52)

1. Bockenstedt L. Lyme disease. In: Firestein G, Budd R, Harris E Jr, McInnes I, Ruddy S, Sergent J, eds. Kelley's Textbook of Rheumatology. St. Louis, Missouri, USA: W.B. Saunders; 2009:1715-1725.
2. Dattwyler RJ, Volkman DJ, Conaty SM, Platkin SP, Luft BJ. Amoxycillin plus probenecid versus doxycycline for treatment of erythema migrans borreliosis. Lancet. 1990;336(8728):1404-1406.
3. Steere AC, Angelis SM. Therapy for Lyme arthritis: strategies for the treatment of antibiotic-refractory arthritis. Arthritis Rheum. 2006;54(10):3079-3086. (Pubitemid 44622076)
4. Aguero-Rosenfeld ME, Wang G, Schwartz I, Wormser GP. Diagnosis of Lyme borreliosis. Clin Microbiol Rev. 2005;18(3):484-509. (Pubitemid 40995113)
5. Barthold SW, Beck DS, Hansen GM, Terwilliger GA, Moody KD. Lyme borreliosis in selected strains and ages of laboratory mice. J Infect Dis. 1990; 162(1):133-138. (Pubitemid 20223961)
6. Brown CR, Reiner SL. Genetic control of experimental Lyme arthritis in the absence of specific immunity. Infect Immun. 1999;67(4):1967-1973. (Pubitemid 29144423)
7. Brown CR, Reiner SL. Bone-marrow chimeras reveal hemopoietic and nonhemopoietic control of resistance to experimental Lyme arthritis. J Immunol. 2000;165(3):1446-1452. (Pubitemid 30604577)
8. Barthold SW, Sidman CL, Smith AL. Lyme borreliosis in genetically resistant and susceptible mice with severe combined immunodeficiency. Am J Trop Med Hyg. 1992;47(5):605-613.
9. Bolz DD, et al. MyD88 plays a unique role in host defense but not arthritis development in Lyme disease. J Immunol. 2004;173(3):2003-2010. (Pubitemid 38971637)
10. Liu N, Montgomery RR, Barthold SW, Bockenstedt LK. Myeloid differentiation antigen 88 deficiency impairs pathogen clearance but does not alter inflammation in Borrelia burgdorferi-infected mice. Infect Immun. 2004;72(6):3195-3203. (Pubitemid 38697740)
11. Wang G, Ma Y, Buyuk A, McClain S, Weis JJ, Schwartz I. Impaired host defense to infection and Toll-like receptor 2-independent killing of Borrelia burgdorferi clinical isolates in TLR2-deficient C3H/HeJ mice. FEMS Microbiol Lett. 2004; 231(2):219-225. (Pubitemid 38251603)
12. Yrjanainen H, Hytonen J, Song XY, Oksi J, Hartiala K, Viljanen MK. Anti-tumor necrosis factor-alpha treatment activates Borrelia burgdorferi spirochetes 4 weeks after ceftriaxone treatment in C3H/He mice. J Infect Dis. 2007;195(10):1489-1496. (Pubitemid 46717467)
13. Hodzic E, Feng S, Holden K, Freet KJ, Barthold SW. Persistence of Borrelia burgdorferi following antibiotic treatment in mice. Antimicrob Agents Chemother. 2008;52(5):1728-1736. (Pubitemid 351614666)
14. Bockenstedt LK, Mao J, Hodzic E, Barthold SW, Fish D. Detection of attenuated, noninfectious spirochetes in Borrelia burgdorferi-infected mice after antibiotic treatment. J Infect Dis. 2002; 186(10):1430-1437. (Pubitemid 35286110)
15. Dunham-Ems SM, et al. Live imaging reveals a biphasic mode of dissemination of Borrelia burgdorferi within ticks. J Clin Invest. 2009;119(12):3652-3665.
16. Pavia C, Inchiosa MA Jr, Wormser GP. Efficacy of short-course ceftriaxone therapy for Borrelia burgdorferi infection in C3H mice. Antimicrob Agents Chemother. 2002;46(1):132-134. (Pubitemid 34031614)
17. Harman M, et al. The heterogeneous motility of the Lyme disease spirochete in gelatin mimics dissemination through tissue. Proc Natl Acad Sci U S A. 2012; 109(8):3059-3064.
18. Wormser GP, et al. Borrelia burgdorferi genotype predicts the capacity for hematogenous dissemination during early Lyme disease. J Infect Dis. 2008; 198(9):1358-1364.
19. Steere AC, Grodzicki RL, Craft JE, Shrestha M, Kornblatt AN, Malawista SE. Recovery of Lyme disease spirochetes from patients. Yale J Biol Med. 1984; 57(4):557-560. (Pubitemid 15151045)
20. Ambrose PG, et al. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin Infect Dis. 2007;44(1):79-86. (Pubitemid 44968990)
21. Wormser GP, Schwartz I. Antibiotic treatment of animals infected with Borrelia burgdorferi. Clin Microbiol Rev. 2009;22(3):387-395.
22. Li X, McHugh GA, Damle N, Sikand VK, Glickstein L, Steere AC. Burden and viability of Borrelia burgdorferi in skin and joints of patients with erythema migrans or Lyme arthritis. Arthritis Rheum. 2011;63(8):2238-2247.
23. Young G, Turner S, Davies JK, Sundqvist G, Figdor D. Bacterial DNA persists for extended periods after cell death. J Endod. 2007;33(12):1417-1420.
24. Brundin M, Figdor D, Roth C, Davies JK, Sundqvist G, Sjogren U. Persistence of dead-cell bacterial DNA in ex vivo root canals and influence of nucleases on DNA decay in vitro. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010;110(6):789-794.
25. Miklossy J, Kasas S, Zurn AD, McCall S, Yu S, McGeer PL. Persisting atypical and cystic forms of Borrelia burgdorferi and local inflammation in Lyme neuroborreliosis. J Neuroinflammation. 2008;5:40.
26. Alban PS, Johnson PW, Nelson DR. Serum-starvation- induced changes in protein synthesis and morphology of Borrelia burgdorferi. Microbiology. 2000; 146(pt 1):119-127. (Pubitemid 30066313)
27. Sonenshein AL. Endospore-forming bacteria, an overview. In: Brun Y, Shimkets L, eds. Prokaryotic Development. Washington, DC, USA: ASM Press; 2000:133-150.
28. Lewis K. Multidrug tolerance of biofilms and persister cells. Curr Top Microbiol Immunol. 2008; 322:107-131.
29. Lewis K. Persister cells. Annu Rev Microbiol. 2010; 64:357-372.
30. Dawson CC, Intapa C, Jabra-Rizk MA. "Persisters": survival at the cellular level. PLoS Pathog. 2011; 7(7):e1002121.
31. Byram R, Stewart PE, Rosa P. The essential nature of the ubiquitous 26-kilobase circular replicon of Borrelia burgdorferi. J Bacteriol. 2004; 186(11):3561-3569. (Pubitemid 38661554)
32. Dunham-Ems SM, Caimano MJ, Eggers CH, Radolf JD. Borrelia burgdorferi requires the alternative sigma factor RpoS for dissemination within the vector during tick-to-mammal transmission. PloS Pathog. 2012;8(2):e1002532.
33. Embers ME, et al. Persistence of Borrelia burgdorferi in Rhesus Macaques following antibiotic treatment of disseminated infection. PLoS One. 2012; 7(1):e29914.
34. Ohnishi J, Piesman J, de Silva AM. Antigenic and genetic heterogeneity of Borrelia burgdorferi populations transmitted by ticks. Proc Natl Acad Sci U S A. 2001;98(2):670-675. (Pubitemid 32105101)
35. Schwan TG, Burgdorfer W, Garon CF. Changes in infectivity and plasmid profile of the Lyme disease spirochete, Borrelia burgdorferi, as a result of in vitro cultivation. Infect Immun. 1988;56(8):1831-1836.
36. Poltorak A, et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in TLR4 gene. Science. 1998;282(5396):2085-2088. (Pubitemid 29001265)
37. Barthold SW, de Souza MS, Janotka JL, Smith AL, Persing DH. Chronic Lyme borreliosis in the laboratory mouse. Am J Pathol. 1993;143(3):959-971.
38. Bradley JF, Johnson RC, Goodman JL. The persistence of spirochetal nucleic acids in active Lyme arthritis. Ann Intern Med. 1994;120(6):487-489. (Pubitemid 24075227)
39. Carlson D, Hernandez J, Bloom BJ, Coburn J, Aversa JM, Steere AC. Lack of Borrelia burgdorferi DNA in synovial samples from patients with antibiotic treatment-resistant Lyme arthritis. Arthritis Rheum. 1999;42(12):2705-2709. (Pubitemid 30327194)
40. Priem S, Burmester GR, Kamradt T, Wolbart K, Rittig MG, Krause A. Detection of Borrelia burgdorferi by polymerase chain reaction in synovial membrane, but not in synovial fluid from patients with persisting Lyme arthritis after antibiotic therapy. Ann Rheum Dis. 1998;57(2):118-121. (Pubitemid 28177543)
41. Gross DM, et al. Identification of LFA-1 as a candidate autoantigen in treatment-resistant Lyme arthritis. Science. 1998;281(5377):703-706. (Pubitemid 28390407)
42. Steere AC, Falk B, Drouin EE, Baxter-Lowe LA, Hammer J, Nepom GT. Binding of outer surface protein A and human lymphocyte function-associated antigen 1 peptides to HLA-DR molecules associated with antibiotic treatment-resistant Lyme arthritis. Arthritis Rheum. 2003;48(2):534-540. (Pubitemid 36278023)
43. Steere AC, et al. Antibiotic-refractory Lyme arthritis is associated with HLA-DR molecules that bind a Borrelia burgdorferi peptide. J Exp Med. 2006; 203(4):961-971.
44. Ghosh S, Seward R, Costello CE, Stollar BD, Huber BT. Autoantibodies from synovial lesions in chronic, antibiotic treatment-resistant Lyme arthritis bind cytokeratin-10. J Immunol. 2006;177(4):2486-2494. (Pubitemid 44201008)
45. Steere AC, Schoen RT, Taylor E. The clinical evolution of Lyme arthritis. Ann Intern Med. 1987; 107(5):725-731. (Pubitemid 18041872)
46. Strle K, Shin JJ, Glickstein LJ, Steere AC. Association of a Toll-like receptor 1 polymorphism with heightened Th1 inflammatory responses and antibioticrefractory Lyme arthritis. Arthritis Rheum. 2012; 64(5):1497-1507.
47. Wormser GP, et al. The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis. 2006;43(9):1089-1134. (Pubitemid 44637131)
48. Feder HM Jr, et al. A critical appraisal of "chronic Lyme disease". N Engl J Med. 2007;357(14):1422-1430.
49. Klempner MS, et al. Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease. N Engl J Med. 2001; 345(2):85-92. (Pubitemid 32634566)
50. Krupp LB, et al. Study and treatment of post Lyme disease (STOP-LD): a randomized double masked clinical trial. Neurology. 2003;60(12):1923-1930. (Pubitemid 36736007)
51. Fallon BA, et al. A randomized, placebo-controlled trial of repeated IV antibiotic therapy for Lyme encephalopathy. Neurology. 2008;70(13):992-1003. (Pubitemid 351451323)
52. Adachi O, et al. Targeted disruption of the MyD88 gene results in loss of IL-1-and IL-18-mediated function. Immunity. 1998;9(1):143-150. (Pubitemid 28361303)